Design and rationale of a randomized study to compare amiodarone and Class IC anti-arrhythmic drugs in terms of atrial fibrillation treatment efficacy in patients paced for sinus node disease: the PITAGORA trial

Gulizia, Michele Massimo; Mangiameli, S; Chiarandà, Giacomo; Spadola, Vincenzo; Giovanni, Nicolò Di; Colletti, Andrea; Bulla, V.; Circo, A; Pensabene, Orazio; Vasquez, Ludovico; Vaccaro, Ignazio; Grammatico, Andrea

doi:10.1093/europace/eul003

Cited by 3 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…European Society of Cardiology guidelines recommend flecainide or propafenone for the long-term control of heart rhythm in AF patients with normal left ventricular function and no structural heart disease (defined as significant LVH and myocardial ischemia). These recommendations are strongly supported by several studies confirming flecainide's efficiency and safety profile [13][14][15]. The 2019 review of the Cochrane Antiarrhythmic Drugs database, based on four randomized controlled trials (RCT) with over 511 participants, confirmed the effectiveness of chronic treatment with flecainide acetate compared to placebo or no treatment (RR 0.65).…”

Section: Long-term Rhythm Controlmentioning

confidence: 93%

Flecainide in clinical practice

et al. 2023

View full text Add to dashboard Cite

show abstract

Section: Long-term Rhythm Controlmentioning

confidence: 93%

Flecainide in clinical practice

et al. 2023

View full text Add to dashboard Cite

show abstract

A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: The Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial

Gulizia

Mangiameli

Orazi³

et al. 2008

American Heart Journal

View full text Add to dashboard Cite

Flecainide: Current status and perspectives in arrhythmia management

Andrikopoulos

Pastromas

Tzeis

2015

WJC

View full text Add to dashboard Cite

Flecainide acetate is a class IC antiarrhythmic agent and its clinical efficacy has been confirmed by the results of several clinical trials. Nowadays, flecainide is recommended as one of the first line therapies for pharmacological conversion as well as maintenance of sinus rhythm in patients with atrial fibrillation and/or supraventricular tachycardias. Based on the Cardiac Arrhythmia Suppression Trial study results, flecainide is not recommended in patients with structural heart disease due to high proarrhythmic risk. Recent data support the role of flecainide in preventing ventricular tachyarrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia associated both with ryanodine receptor and calsequestrin mutations. We herein review the current clinical data related to flecainide use in clinical practice and some concerns about its role in the management of patients with coronary artery disease.

show abstract

Design and rationale of a randomized study to compare amiodarone and Class IC anti-arrhythmic drugs in terms of atrial fibrillation treatment efficacy in patients paced for sinus node disease: the PITAGORA trial

Abstract: Given the high morbidity and healthcare costs associated with AF, new therapeutic strategies are needed. The results of the PITAGORA trial may help in guiding AADs therapy and ATP programming in SND patients suffering from AF.

Cited by 3 publications

References 33 publications

Flecainide in clinical practice

Flecainide in clinical practice

A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: The Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial

Flecainide: Current status and perspectives in arrhythmia management

Contact Info

Product

Resources

About